Table 2. The HRs/ORs value and concomitant variables of included studies.
| Author | Year | Distant metastasis (OR/HR) | lymph node metastasis (OR/HR) | Survival analysis | HR (95% CI) | P | Concomitant variables |
|---|---|---|---|---|---|---|---|
| Li J5 | 2008 | 9.930 (2.200–44.820) | 1.714 (0.999–2.943) | OS (M) | 2.906 (1.810–4.668) | <0.001 | T classification, N classification. |
| Hu GH14 | 2009 | 4.280 (1.320–13.900) (M) | / | CSS (U) | 8.300 (1.894–36.376) | 0.005 | ER, PR, HER2, p53 and tumor size. |
| Su P15 | 2010 | / | 1.094 (0.587–2.038) | / | / | / | |
| Li C16 | 2011 | 3.875 (1.647–9.118) | 3.188 (1.524–6.671) | OS (M) | 3.484 (1.505–8.062) | <0.001 | tumor size, lymphatic and venous invasion, lymph node status. |
| DFS (M) | 3.032 (1.388–6.622) | 0.014 | |||||
| Tokunaga E23 | 2014 | 2.39 (1.08–5.01) (M) | 1.771 (0.861–3.642) | DFS (M) | 3.450 (1.690–6.840) | 0.001 | tumor size, nodal involvement, nuclear grade, lymphovascular invasion, ER, PR, HER2. |
| OS (U)a | 1.950 (1.173–3.241) | 0.01 | |||||
| Tan LS25 | 2015 | 2.604 (1.084–6.257) | 3.900 (1.724–8.821) | OS (U)a | 3.140 (1.230–8.010) | 0.017 | |
| DFS (U)a | 2.540 (1.140–5.660) | 0.023 | |||||
| Meng F6 | 2011 | / | / | OS (M) | 5.573 (2.199–14.124) | <0.001 | FIGO stage, residual tumor, histological type. |
| DFS (M) | 3.982 (1.913–8.286) | <0.001 | |||||
| Li C17 | 2011 | 8.541 (2.561–37.461) (M) | 9.581 (2.613–23.214) (M) | / | / | / | FIGO stage, residual tumor size. |
| Li C18 | 2011 | / | / | OS (M) | 19.380 (7.518–34.192) | <0.001 | age, lymph node metastasis, histopathological differentiation, serum CA-125 level, cytoreduction, FIGO stage, residual tumour size, chemotherapy resistance. |
| Li C22 | 2014 | / | / | OS (M) | 2.673 (1.445–4.867) | 0.002 | age, primary malignancies, extent of disease, ascites, size, time to diagnosis. |
| Dong R20 | 2014 | / | / | OS (U)a | 1.280 (1.004–1.631) | 0.046 | |
| DFS (U)a | 1.200 (0.989–1.456) | 0.065 | |||||
| Zhou B26 | 2015 | / | 10.588 (1.312–85.438) | OS (M) | 3.037 (1.067–8.670) | 0.036 | age, histological type, differentiation degree, lymph node metastasis, clinical stage. |
| Huang K7 | 2013 | / | 4.050 (1.565–10.481) | OS (M) | 4.021 (1.734–8.283) | 0.027 | age, tumor size, histological classification, clinical stage, pathological grade, lymph node metastasis. |
| Song EL24 | 2014 | / | / | OS (U)a | 1.790 (1.105–2.900) | 0.018 | |
| Long M19 | 2013 | 6.781 (0.388–118.631) | 18.616 (1.110–312.323) | / | / | / | |
| Song HT8 | 2010 | / | 3.929 (1.437–10.743) | OS (M) | 4.960 (1.774–13.869) | 0.002 | FIGO stage, lymphatic and venous invasion, histological type. |
| DFS (M) | 3.573 (1.499–8.518) | 0.004 | |||||
| Wang Y27 | 2016 | / | 2.500 (1.101–5.676) | OS (M) | 8.644 (4.255–17.556) | <0.001 | FIGO stage, residual tumor. |
| DFS (M) | 5.132 (2.943–8.949) | <0.001 | |||||
| Jin P28 | 2013 | 4.429 (1.373–14.283) | 1.699 (1.145–4.230) | DFS (U)a | 2.710 (1.070–6.900) | 0.036 |
HR: hazard ratio; OR: odds ratios; OS: overall survival; CSS: cancer-specific survival; DFS: disease-free survival; M: multivariate analysis; U: univariate analysis;
aextracted from survival curve; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2; FIGO: International Federation of Gynecology and Obstetrics.